Pas de connexion internet — affichage de la version enregistrée de la page.

Corcept Therapeut…

USUSD
← Vers le Screener
US:CORTLSE:0I3Q

Corcept Therapeutics Incorporated (LSE:0I3Q) — Biotechnology: Pharmaceutical Preparations. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 2. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site Web
corcept.com
Relations avec les Investisseurs
ir.corcept.com/
Secteur
Health Care · Biotechnology: Pharmaceutical Preparations
Siège Social
Menlo Park, United States
PDG
Joseph K. Belanoff
Employés
730
Fondée
1998
Actions en Circulation
108.1 M au 2026-07-22
Flottant
96.47 M
Capitalisation Boursière
12.4 Md USD
Initiés
11.47%
Investisseurs Institutionnels
76.86%
Secteur d'Activité (SIC)
Pharmaceutical Preparations
ISIN
US2183521028
LEI
529900EO9LUTFMZ7FF90
FCF
107 M USD
Dette
0 USD
trésorerie nette
Résultats et FCF — pour les 12 mois à 30.06.2026 (dernier rapport de l'entreprise).
NAV
6.53 USD · P/NAV 17.7
Balance sheet date30.06.2026
Assets889 M USD
− Liabilities183 M USD
= NAV (capitaux propres des actionnaires de la société)706 M USD
= Tangible NAV706 M USD
Actions108 098 397
NAV per share6.53 USD
VLV Tangible par Action6.53 USD
Share price (0I3Q)115.72 USD
P/NAV17.72
NAV history
Balance sheet dateNAVNAV per share
30.06.2026706 M USD6.53 USD
31.03.2026638 M USD5.94 USD
31.12.2025648 M USD6.11 USD
30.09.2025632 M USD6.01 USD
30.06.2025636 M USD6.03 USD
31.03.2025683 M USD6.44 USD
31.12.2024680 M USD6.47 USD
30.09.2024639 M USD6.10 USD
Description

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

publicité

Bourses et Tickers

BourseTickerDevisePrixType
US USA StocksCORT principaleUSD116.23 -1.33%actions ordinaires
LSE London Stock Exchange0I3Q IOBUSD115.72 +0.00%actions ordinaires

Cours sur 3 Mois

jour de hausse jour de baisseSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Principaux Actionnaires

DétenteurParticipationActionsDate du Rapport
Blackrock Inc.11.5%12.43 M2026-06-30
Ingalls & Snyder LLC7.34%7.93 M2026-06-30
iShares Trust-iShares Co…5.39%5.82 M2026-08-31
BAKER GEORGE LEONARD JR.…≈5.14%5.55 M2026-03-17
Renaissance Technologies…4.87%5.26 M2026-06-30
Vanguard Portfolio Manag…4.67%5.04 M2026-06-30
Vanguard Capital Managem…3.86%4.17 M2026-06-30
Parallel Advisors, LLC3.67%3.96 M2026-06-30
FMR, LLC3.09%3.34 M2026-06-30
State Street Corporation3.03%3.28 M2026-06-30
VANGUARD INDEX FUNDS-Van…2.68%2.89 M2026-06-30
AQR Capital Management,…2.39%2.58 M2026-06-30
Geode Capital Management…2.34%2.53 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.94%2.09 M2026-06-30
Fidelity Contrafund1.35%1.46 M2026-07-31
VANGUARD INDEX FUNDS-Van…1.12%1.21 M2026-06-30
VANGUARD INDEX FUNDS-Van…1.01%1.1 M2026-06-30
First TRT Exch-Trd Fd.-F…0.91%985 3772026-08-31
iShares Trust-iShares S&…0.84%903 8952026-08-31
SPDR SERIES TRUST-State…0.83%898 8812026-08-31
VANGUARD TAX-MANAGED FUN…0.57%615 7852026-06-30
HUNT HAZEL (Officer)≈0.24%255 4372026-02-09
MADUCK SEAN (Officer)≈0.11%119 6552026-09-01
ROBB GARY CHARLES (Offic…≈0.07%74 3432026-09-24
MOKARI ATABAK (Chief Fin…≈0.02%16 3042026-09-01
LYON JOSEPH DOUGLAS (Chi…≈0.01%5 6832026-09-14
GUYER WILLIAM (Officer)≈0%4 3132026-09-01
BELANOFF JOSEPH K (Chief…——2026-06-01
MAHONEY DAVID L (Directo…——2026-08-18
WILSON JAMES N (Director…——2026-09-15